Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: A case report

Therapeutic Drug Monitoring

Volumn 36, Issue 5, 2014, Pages 687-689

  Pea, Federico ^a,b   Cadeo, Barbara ^a   Cojutti, Pier G ^a,b   Pecori, Davide ^a   Bassetti, Matteo ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DAPTOMYCIN; DOXYCYCLINE; LEVOTHYROXINE; LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE; THYROXINE;

ADULT; ANTIBIOTIC THERAPY; CASE REPORT; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG MONITORING; HOSPITAL DISCHARGE; HUMAN; HYPOTHYROIDISM; LETTER; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; SUBSTITUTION THERAPY; BLOOD; DRUG INTERACTION; FEMALE; SOFT TISSUE INFECTIONS;

ACETAMIDES; ADULT; ANTI-INFECTIVE AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOTHYROIDISM; OXAZOLIDINONES; SOFT TISSUE INFECTIONS; THYROXINE;

EID: 84930182478     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000069     Document Type: Letter

References (12)

1. Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: A retrospective monocentric analysis. Antimicrob Agents Chemother. 2010;54:4605-4610.
2. Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of longterm treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67:2034-2042.
3. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42: 1129-1140.
4. Yagi T, Naito T, Doi M, et al. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients. Int J Antimicrob Agents. 2013;42:329-334.
5. Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents. 2008;31:122-129.
6. Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy. 2007;27:476-479.
7. Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51:229-236.
8. Siegmund W, Altmannsberger S, Paneitz A, et al. Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin Pharmacol Ther. 2002;72:256-264.
9. Nishio N, Katsura T, Ashida K, et al. Modulation of P-glycoprotein expression in hyperthyroid rat tissues. Drug Metab Dispos. 2005;33: 1584-1587.
10. Mitin T, Von Moltke LL, Court MH, et al. Levothyroxine up-regulates P-glycoprotein independent of the pregnane X receptor. Drug Metab Dispos. 2004;32:779-782.
11. Nishio N, Katsura T, Inui K. Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells. Pharm Res. 2008;25:1037-1042.
12. Jin M, Shimada T, Shintani M, et al. Longterm levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine. Drug Metab Pharmacokinet. 2005;20:324-330.